Pieris Pharmaceuticals Inc (PIRS): Price-to-Sales Ratio

Corporate company logo of Pieris Pharmaceuticals Inc (PIRS)

Pieris Pharmaceuticals (PIRS) aims for the global implementation of Anticalin protein technologies to combat cancer and lung diseases, while the P/S ratio history is available for analysis on GURU.Markets, where the 821.20 level serves as a critical benchmark. The current restructuring following the dissolution of major alliances requires strict regulatory oversight, and development relies on attracting leading biologists through competitive salaries.

Pieris (PIRS): P/S Multiple from 07/04/2022 to 12/31/2025

Analytical breakdowns for Pieris (PIRS)

- share price and consensus valuation forecast:
Price Performance Chart pieris.com|PIRS - Price Target Chart
- stock exchange capitalization data:
Market Valuation Pieris|PIRS - Enterprise Value
- balance sheet net asset value indicators:
Net Assets per Share Pieris Pharmaceuticals|PIRS - Book Capitalization|Market-to-Book Ratio pieris.com|PIRS - Aggregate Company Assets
- debt obligations and liquidity statistics:
All Debt to Shareholders' Equity Ratio Pieris Pharmaceuticals|PIRS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Pieris Pharma|PIRS - Company Debts|Debts to Net Assets Pieris|PIRS - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Pieris Pharmaceuticals|Critical Liquidity Ratio pieris.com
- net income and valuation ratios data:
PIRS - Net Profit|Expected Net Income Pieris Pharmaceuticals|PIRS - P/E Multiple|Forward P/E Multiple Pieris Pharmaceuticals Inc|PIRS - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation Pieris|PIRS - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Pieris Pharmaceuticals|PIRS - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pieris.com|PIRS - Earnings growth in current year|Expected earnings per share growth for next year Pieris Pharmaceuticals
- issuer revenue and sales details:
PIRS - Revenue and Sales Volume|Company Expected Sales Volume pieris.com|PIRS - Market Cap to Revenue|Forward P/S Multiple Pieris
Fundamental company analysis:PIRS, pieris.com
Finished products of Pieris Pharmaceuticals

Evaluating market value relative to generated income is critical for selecting assets with a high margin of safety. This price-to-sales ratio correlates the market capitalization of Pieris Pharmaceuticals (PIRS) with licensing revenue from anti-calin proteins and royalties from AstraZeneca and Servier, allowing investors to determine the premium paid for innovative drug potential by analyzing the historical trend of this metric.

Who Pieris Pharmaceuticals competes with

HLN (haleon.com) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue KVUE|VRNA (Verona Pharma PLC) - Price-to-Sales Ratio|Jyong Biotech Corp - P/S Multiple|Price-to-Revenue Coefficient Ligand Corp LGND|AMRX: P/S Multiple|Price to Sales perrigo.com (PRGO)|Price-to-Revenue Ratio Alvotech SA|LQDA: Market Capitalization-to-Revenue Ratio|P/S Multiple GLPG|Price-to-Revenue Coefficient ANI Pharmaceuticals Corp|Price-to-Revenue Ratio MannKind Corporation MNKD|Price-to-Revenue Coefficient amphastar.com (AMPH)|PCRX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio SPRY (ARS Pharmaceuticals Inc)|Theravance (TBPH) - Price-to-Revenue Ratio|Price-to-Sales Ratio AQST (Aquestive Corp)|SCPH (scPharmaceuticals, Inc.) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|P/S Multiple TNXP|P/S Multiple sxtchina.com (SXTC)|Price-to-Revenue Ratio Eupraxia Pharmaceuticals Inc. EPRX|Market Capitalization-to-Revenue Ratio BHST|EXOZ - Price-to-Revenue Ratio|Oramed Pharmaceuticals (ORMP) - Market Cap to Revenue|ENTX: P/S Multiple|MindWalk Holdings, Inc. (HYFT) - P/S Multiple|ABVC (ABVC BioPharma Inc) - P/S Multiple|Market Cap to Revenue Cumberland Corp (CPIX)|P/S Multiple QNTM|FGEN - Price to Sales|Telomir Pharmaceuticals, Inc. - Market Cap to Revenue|P/S Multiple Rani Therapeutics Holdings RANI|SNYR: Market Cap to Revenue|Rallybio Corporation - Market Cap to Sales Volume|LEXX: P/S Multiple|PULM - Price-to-Revenue Coefficient|PTHL (Pheton Holdings Limited) - P/S Multiple|Market Cap to Revenue Aptorum (APM)|P/S Multiple LYRA|P/S Multiple Impact BioMedical, Inc. (IBO)|Price-to-Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|cbdMD Inc. - Price-to-Revenue Ratio|PRFX - Price-to-Revenue Ratio|Price-to-Revenue Coefficient Altamira Therapeutics CYTO|Lipella (LIPO) - Price-to-Revenue Ratio|Price-to-Sales Ratio OPTN (OptiNose Corp)|PROC (Procaps Group S.A.) - P/S Multiple|petrospharma.com (PTPI) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Qilian International Holding (QLI)|SLRN (Acelyrin Inc.) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio TFF Pharma TFFP